CGC vs. CRON, USNA, MNMD, ACB, BTMD, SLNO, ARDX, DAWN, KURA, and ADMA
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Cronos Group (CRON), USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), Aurora Cannabis (ACB), biote (BTMD), Soleno Therapeutics (SLNO), Ardelyx (ARDX), Day One Biopharmaceuticals (DAWN), Kura Oncology (KURA), and ADMA Biologics (ADMA). These companies are all part of the "medical" sector.
Cronos Group (NASDAQ:CRON) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
Cronos Group has a net margin of -84.15% compared to Cronos Group's net margin of -326.75%. Canopy Growth's return on equity of -3.99% beat Cronos Group's return on equity.
Cronos Group has higher earnings, but lower revenue than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 2.0% of Cronos Group shares are held by insiders. Comparatively, 0.4% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Cronos Group received 444 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 61.21% of users gave Cronos Group an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
Cronos Group has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Cronos Group currently has a consensus target price of $2.83, indicating a potential upside of 6.52%. Canopy Growth has a consensus target price of $4.87, indicating a potential downside of 52.98%. Given Canopy Growth's stronger consensus rating and higher probable upside, research analysts plainly believe Cronos Group is more favorable than Canopy Growth.
In the previous week, Canopy Growth had 14 more articles in the media than Cronos Group. MarketBeat recorded 24 mentions for Canopy Growth and 10 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.85 beat Canopy Growth's score of 0.23 indicating that Canopy Growth is being referred to more favorably in the news media.
Summary
Cronos Group beats Canopy Growth on 14 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
